Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.58 |
| ▸ | CNR2 | P34972 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29001876 | 0.86 | AOC3 (0.60) | AOC3CNR2MEN1KMT2AALDH1A1 | |
| SCHEMBL17115661 | 0.84 | AOC3 (0.58) | AOC3CNR2MEN1KMT2AALDH1A1 | |
| SCHEMBL28030690 | 0.82 | AOC3 (0.61) | AOC3CNR2MEN1KMT2AALDH1A1 | |
| SCHEMBL17316664 | 0.82 | ALDH1A1 (0.52) | AOC3ALDH1A1HPGDHSD17B10CA2 | |
| SCHEMBL5449533 | 0.82 | ALDH1A1 (0.61) | CNR2ALDH1A1HPGDHSD17B10CA2 | |
| SCHEMBL27921971 | 0.80 | ALDH1A1 (0.45) | AOC3CNR2MEN1KMT2AALDH1A1 | |
| SCHEMBL20369135 | 0.79 | ALDH1A1 (0.49) | CNR2ALDH1A1HPGDHSD17B10CA2 | |
| SCHEMBL202439 | 0.79 | CA2 (0.56) | CNR2MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL14496299 | 0.79 | ALDH1A1 (0.60) | CNR2ALDH1A1HPGDHSD17B10NR3C1 | |
| SCHEMBL12102412 | 0.78 | NR3C1 (0.50) | MEN1KMT2AALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106414429-B | Pyrazole compounds and their use as T-type calcium channel blockers | 爱杜西亚药品有限公司 | 2020-01-03 | — | — | CN | disclosed |
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-09-04 | — | — | US | disclosed |
| US-9932314-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-03 | — | — | US | disclosed |
| EP-3152199-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | Actelion Pharmaceuticals Ltd. (CH) | 2017-04-12 | — | — | EP | disclosed |
| US-20170096399-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-04-06 | — | — | US | disclosed |
| CN-106414429-A | Pyrazole compounds and their use as T-type calcium channel blockers | 埃科特莱茵药品有限公司 | 2017-02-15 | — | — | CN | disclosed |
| WO-2015186056-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-10 | — | — | WO | disclosed |
| US-20100178250-A1 | Method of Local Delivery of Bioactive and Diagnostic Agents Using Magnetizable Bone Cement | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-20080319247-A1 | Method of local therapy using magnetizable thermoplastic implant | PHILADELPHIA HEALTH & EDUCATION CORPORATION D/B/A DREXEL UNIVERSITY COLLEGE OF MEDICINE (US) | 2008-12-25 | — | — | US | disclosed |
| WO-2008024675-A2 | METHOD OF LOCAL DELIVERY OF BIOACTIVE AND DIAGNOSTIC AGENTS USING MAGNETIZABLE BONE CEMENT | PHILADELPHIA HEALTH & EDUCATION CORPORATION D/B/A DREXEL UNIVERSITY COLLEGE OF MEDICINE (US) | 2008-02-28 | — | — | WO | disclosed |
| EP-0361408-B1 | Improved bone cement | WOLLF & KAABER AS (DK) | 1993-11-24 | — | — | EP | disclosed |
| WO-1990003193-A1 | BONE CEMENT | WOLFF & KAABER A/S (DK) | 1990-04-05 | — | — | WO | disclosed |
| EP-0361408-A2 | Improved bone cement | Wolff & Kaaber A/S (DK) | 1990-04-04 | — | — | EP | disclosed |
| US-4910259-A | Acrylated polymer | WOLFF & KAABER A/S (DK) | 1990-03-20 | — | — | US | disclosed |
| US-4486179-A | ESTERS OF SYRINGIC ACID AS ANTICARIES AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1984-12-04 | — | — | US | disclosed |
| US-4362510-A | ESTER OF VANILLIC ACID, METAL OXIDE OR HYDROXIDE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1982-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | CACNA1E, CACNA1I, CACNA1G | AOC3 2118/4885CNR2 279/4885MEN1 711/4885 |
| US-20170096399-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1I, CACNA1G | AOC3 2118/4885CNR2 279/4885MEN1 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.